|
ASSAY and Drug Development Technologies
A Robotic Platform for Quantitative High-Throughput Screening
To cite this article:
Sam Michael, Douglas Auld, Carleen Klumpp, Ajit Jadhav, Wei Zheng, Natasha Thorne, Christopher P. Austin, James Inglese, Anton Simeonov.
ASSAY and Drug Development Technologies.
October 2008,
6(5): 637-658.
doi:10.1089/adt.2008.150.
Published in Volume: 6 Issue 5: November 27, 2008
Sam Michael NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Douglas Auld NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Carleen Klumpp NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Ajit Jadhav NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Wei Zheng NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Natasha Thorne NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Christopher P. Austin NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. James Inglese NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Anton Simeonov NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. High-throughput screening (HTS) is increasingly being adopted in academic institutions, where the decoupling of screening and drug development has led to unique challenges, as well as novel uses of instrumentation, assay formulations, and software tools. Advances in technology have made automated unattended screening in the 1,536-well plate format broadly accessible and have further facilitated the exploration of new technologies and approaches to screening. A case in point is our recently developed quantitative HTS (qHTS) paradigm, which tests each library compound at multiple concentrations to construct concentration–response curves (CRCs) generating a comprehensive data set for each assay. The practical implementation of qHTS for cell-based and biochemical assays across libraries of > 100,000 compounds (e.g., between 700,000 and 2,000,000 sample wells tested) requires maximal efficiency and miniaturization and the ability to easily accommodate many different assay formats and screening protocols. Here, we describe the design and utilization of a fully integrated and automated screening system for qHTS at the National Institutes of Health's Chemical Genomics Center. We report system productivity, reliability, and flexibility, as well as modifications made to increase throughput, add additional capabilities, and address limitations. The combination of this system and qHTS has led to the generation of over 6 million CRCs from > 120 assays in the last 3 years and is a technology that can be widely implemented to increase efficiency of screening and lead generation.  This paper was cited by:A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance Kyle R. Brimacombe, Matthew D. Hall, Douglas S. Auld, James Inglese, Christopher P. Austin, Michael M. Gottesman, King-Leung Fung ASSAY and Drug Development Technologies. Jun 2009, Vol. 7, No. 3: 233-249 Abstract | Full Text PDF | Reprints & Permissions
|
|